A preliminary clinical application of sICAM-1 RIA in three kinds of thyroid disease.
OBJECTIVE
To examine serum levels of sICAM-1 from normal controls and patients with thyroid diseases (simple goitre, Graves' disease or Hashimoto's thyroiditis) with (125)I-sICAM-1 RIA established in our lab.


METHODS
Using (125)I-sICAM-1 RIA, serum sICAM-1 levels of 400 healthy individuals as the normal group and 1020 patients with simple goitre (SG), Graves' disease (GD) or Hashimoto's thyroiditis (HT) were examined for a comporative chinical study.


RESULTS
The serum level of sICAM-1 (x +/- s) in the normal group was 168.43 +/- 36.23 micro g/L. There was no significant difference between the normal and SG groups (P > 0.05), whereas the serum levels of sICAM-1 in autoimmune thyroid diseases (GD or HT) were higher than those in the normal or SG groups (P < 0.05, respectively). After GD patients received one of three medical treatments, their serum sICAM-1 levels decreased (P < 0.05). After GD patients were treated and their thyroid function decreased to normal, their serum sICAM-1 levels were lower than those in relapsed GD patients (P < 0.05).


CONCLUSIONS
sICAM-1 RIA can be used to examine autoimmune thyroid diseases. Serum levels of sICAM-1 can be used as a parameter in diagnosing autoimmune thyroid disease and in evaluating the effects of therapy, drug administration or relapse in GD.
Lu
Mei
M
Department of Nuclear Medicine, General Hospital of Tianjin Medical University, Tianjin 300052, China. lumei888@yahoo.com
Fang
Peihua
P
Zhang
Zhiyou
Z
He
Hongpeng
H
Gao
Shuo
S
Hou
Bingzhang
B
Zheng
Rongxiu
R
Xiao
Qian
Q
Yang
Liping
L
D000328:Adult; D000368:Aged; D005260:Female; D006042:Goiter / Q000097:blood* / Q000175:diagnosis; D006111:Graves Disease / Q000097:blood*; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011863:Radioimmunoassay; D013967:Thyroiditis, Autoimmune / Q000097:blood* / Q000175:diagnosis
D018799:Intercellular Adhesion Molecule-1